PMID-18931881 – PNC-28 Penetratin Causes Tumor Necrosis Not Apoptosis
Sookraj KA, Bowne WB, Adler V, et al. The penetratin sequence in the anticancer PNC-28 peptide causes tumor cell necrosis rather than apoptosis of human pancreatic cancer cells. Ann Surg Oncol. 2009;16(2):497-509.
Quick Reference
| Property | Value |
|---|---|
| PMID | 18931881 |
| DOI | 10.1245/s10434-008-0222-5 |
| Year | 2009 |
| Journal | Annals of Surgical Oncology |
| Study Type | In vitro |
| Evidence Level | V |
| Sample | PANC-1 pancreatic cancer cells, normal fibroblasts |
| Peptide(s) Studied | PNC-28 |
Key Findings
- PNC-28 causes tumor cell death via necrosis, not apoptosis
- Treatment did not elevate proapoptotic proteins (Bax, cytochrome c, caspase-3) — ruling out classical apoptosis pathway
- Rapid LDH release confirmed membrane disruption as the killing mechanism
- Dose-dependent membrane pore formation observed by confocal microscopy
- The penetratin (cell-penetrating peptide) leader sequence is essential for the membranolytic activity
- Normal fibroblasts were unaffected at concentrations that killed cancer cells
Study Design
In vitro mechanistic study using PANC-1 human pancreatic cancer cells and normal fibroblasts. Cell death mechanism characterized by: LDH release assay (necrosis marker), caspase-3 activity assay, Western blot for apoptotic markers (Bax, Bcl-2, cytochrome c), confocal microscopy for membrane integrity, and PI/Annexin V flow cytometry. Peptide truncation and mutation studies used to identify essential domains.
Limitations
- In vitro only
- Single cancer cell line (PANC-1) for mechanistic studies
- Role of the penetratin domain vs. p53 domain not fully disentangled
- Stability of PNC-28 in biological fluids not characterized
Clinical Relevance
This study clarified that PNC-28 kills cancer cells via a necrotic (membrane-lytic) mechanism rather than apoptosis. This distinction is therapeutically significant because many cancer cells develop apoptosis resistance — a necrotic mechanism bypasses this resistance. The penetratin leader sequence was shown to be critical, distinguishing PNC-28 from simple p53 peptide fragments. The finding that normal cells are spared reinforces the therapeutic window.
Related
#research #in-vitro #PNC-28 #evidence-level-V #cancer-therapeutic